1. HREC’s approval was based on several factors, including the strong tolerability observedacross all doses administered to date. Fundamentals just got stronger
2. CEO comes out yesterday to say that big pharma is looking at this novel drug for cardiovascular space
3. CEO, management and major share holders increasing their holdings
4. Peers in same space which trade at a 100 million market cap. NYR has larger potential than each of them and greater market reach in a 60 billion dollar unmet market
5. only drug in the world to protect the heart in any heart attack
6. NA-1 already proved up inhibiting calcium protects the brain in humans and AGN coming up will do the same
37 million market cap is severely undervalued. 50-60 cents target to sit with peers. Aptoll received a multi billion dollar licence agreement and 200 million upfront from Merck for a 10 percent protection compared to placebo. In 12-18 months NYR will be poured over with money from big pharma
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)